四環醫藥(00460.HK):注射用泮托拉唑鈉及布洛芬注射液中選第四批國家藥品集中採購目錄
格隆匯 2 月 4日丨四環醫藥(00460.HK)發佈公吿,集團的注射用泮托拉唑鈉(泮唑爾® 40mg╱支)及布洛芬注射液(法蘭芬® 4ml:0.4g,特納安® 8ml:0.8g)在第四批國家組織藥品集中採購中突出重圍,成功中選。此次集採有超過120家藥企參與競爭,涉及45個品種,80個品規,其中注射劑8個。
集團中選的注射用泮托拉唑鈉是消化領域重要的一線產品。注射用泮托拉唑鈉在國內上市較早,整體市場銷售額較大。2019年IQVIA數據顯示,注射用泮托拉唑鈉屬於超40億元的重磅單品,在質子泵抑制劑(PPI)市場佔有重要地位。根據第四批《全國藥品集中採購文件》的招標規則,本輪注射用泮托拉唑鈉採購週期原則上為一年。
集團一直積極參與帶量採購工作,並以安全、有效、經濟的產品獲得了國家和社會的認可。品質如山,是集團對社會的莊嚴承諾。集團引進歐洲生產設計管理系統,採用高標準製備工藝,生產基地所擁有原料藥、大小容量注射劑、凍乾粉針劑、片劑、膠囊劑、顆粒劑等生產線,均獲國家新版良好生產規範(GMP)認證,並通過美國食品藥品管理局(FDA)現場檢測。在保證質量前提下持續降低成本,憑此優勢,集團能夠在投標中報出有競爭力的價格,引領仿製藥價格下降,提高患者用藥可及性。相信隨着泮托拉唑鈉的成功中選,將為更多患者帶來治療獲益,也將對集團的經營業績產生積極影響。
此次布洛芬注射液的集採四家企業中選三家,採購量為總量的70%。鎮痛領域是集團的新興領域,這勢必給一線銷售注入一劑強心劑,洽談商業,列名醫院將是下一步工作重點,全力執行政策,圓滿完成採購任務。布洛芬作為非選擇性非類固醇消炎止痛藥(NSAIDs)代表藥物,臨牀使用多年。集團於2020年2月取得布洛芬注射液生產批件,視同通過注射劑一致性評價。布洛芬注射液能夠抑制炎症因子釋放,發揮鎮痛抗炎作用,安全性好,不良反應少,有效緩解中樞痛和外周痛,被多指南共識推薦用於多模式鎮痛方案中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.